As the COVID-19 pandemic became more serious, the Endocrine Society joined a coalition of bone health organizations that united to issue new osteoporosis treatment guidelines.
Aside from addressing the challenges social distancing has placed on treating these patients, the coalition has also focused on the administration of osteoporosis medications including denosumab, teriparatide, abaloparatide, romosozumab, and IV bisphosphonates.
The guidelines address social distancing issues for treating patients with osteoporosis, including those who receive treatment through injection or intravenous (IV) delivery of drugs. It also provides guidance on how some patients may be transitioned to alternative therapies until they are able to resume their original treatment.
“We are proud to be part of this coalition, led by American Society for Bone and Mineral Research, of healthcare providers working together to ensure patients with osteoporosis receive the care they need during such uncertain times,” says Endocrine Society president Gary D. Hammer, MD, PhD. “We hope these recommendations offer clear guidance for clinicians who are determined to reduce their patients’ risk of fracture.”
“We are proud to be part of this coalition, led by American Society for Bone and Mineral Research, of healthcare providers working together to ensure patients with osteoporosis receive the care they need during such uncertain times.” – Endocrine Society president Gary D. Hammer, MD, PhD
Worldwide, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds. In the United States, 10.2 million women and men age 50 and above have osteoporosis and 43.4 million Americans over 50 have low bone mass and are at a higher risk of fracture.
With social distancing mandates in place across the nation, many patients are avoiding treatment, and testing and diagnoses are delayed.
“The scale of the COVID-19 pandemic is unprecedented. There is a paucity of data to provide clear guidance for healthcare professionals on how to adjust treatment for these patients to oral bisphosphonates,” says incoming American Society for Bone and Mineral Research (ASBMR) President Suzanne Jan De Beur, MD, who is also a member of the Endocrine Society. “These recommendations and the supporting evidence provide a roadmap to clinicians and their patients.”
When possible, patients should continue their prescribed osteoporosis regimens. Specific recommendations for patients who are unable to receive their next dosage of non-oral osteoporosis medications during the COVID-19 pandemic include:
- For patients who are taking denosumab (Prolia®), experts recommend considering a delay in treatment. If the delay exceeds 1 month (i.e. is 7 months from the most recent prior injection), consider temporary transition to oral bisphosphonate.
- For patients who are taking teriparatide (Forteo®) or abaloparatide (Tymlos®), or romosozumab (Evenity®), experts recommend considering a delay in treatment. If the delay exceeds 3 months, consider temporary transition to oral bisphosphonate.
- For patients who are on IV bisphosphonates, delays of even several months are unlikely to be harmful.
Aside from the Endocrine Society, this coalition includes ASBMR, the American Association of Clinical Endocrinologists (AACE), and the European Calcified Tissue Society (ECTS).